The Board estimates that a further A$15 – 22m (US12 – 17m) will be required to fund theinvestors and this process will commence on completion of the capital raising.
completion of the FDA clinical trial and submission for approval for sale and working capital
requirements. It is expected that this funding will be secured from international strategic
Decision for CE Mark is within 3 weeks.
Approximately 65% of EMA review questions completely resolved.
